Generation Bio Co. announced terminate the employment of Douglas Kerr, M.D., Ph.D., M.B.A., the Company?s Chief Medical Officer, and Tracy Zimmermann, Ph.D., the Company?s Chief Development Officer, effective as of January 28, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.1 USD | -2.52% | +6.53% | +87.88% |
Apr. 12 | Transcript : Generation Bio Co. - Special Call | |
Mar. 07 | Needham Cuts Price Target on Generation Bio to $10 From $14, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+87.88% | 206M | |
+2.93% | 108B | |
-1.02% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |
- Stock Market
- Equities
- GBIO Stock
- News Generation Bio Co.
- Generation Bio Co. Announces Termination of Executives, Effective on January 28, 2024